Action of corilagin on hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats

• Published in: Chemico-biological interactions Vol. 299; pp. 186 - 193
• Main Authors: Nandini, H.S., Naik, Prakash Ramachandra
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.02.2019
• Subjects: Animals; Antidiabetic; Antihyperlipidemic; Antioxidant; Blood Glucose - analysis; Body Weight - drug effects; Catalase - metabolism; Corilagin; Diabetes mellitus; Diabetes Mellitus, Experimental - chemically induced; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - pathology; Glucosides - pharmacology; Glucosides - therapeutic use; Glutathione - metabolism; Glycated Hemoglobin A - analysis; Hydrolyzable Tannins - pharmacology; Hydrolyzable Tannins - therapeutic use; Hyperglycemia - pathology; Hyperglycemia - prevention & control; Hyperlipidemias - pathology; Hyperlipidemias - prevention & control; Insulin - blood; Lipids - blood; Male; Oxidative Stress - drug effects; Rats; Rats, Wistar; Streptozocin - toxicity; Streptozotocin; Superoxide Dismutase - metabolism; Antihyperlipidemic; Corilagin; Antioxidant; Streptozotocin; Diabetes mellitus; Antidiabetic
• ISSN: 0009-2797; 1872-7786
• DOI: 10.1016/j.cbi.2018.12.012

Diabetes mellitus is the world's most common endocrine disease involving metabolic disorders of carbohydrate, protein and fat. This study was undertaken to investigate the anti-diabetic activity of corilagin, a member of polyphenolic tannins used against hyperglycemia and many other diseases in well-known animal models. Diabetes was induced chemically by intraperitoneal administration of Streptozotocin (40 mg/kg bw) to albino Wistar rats. Diabetic rats showed significant increase in the levels of fasting blood glucose, glycated haemoglobin, total cholesterol, triglyceride, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, and a significant decrease in the level of body weight, plasma insulin, high density lipoprotein cholesterol, antioxidant activities, viz. superoxide dismutase, catalase and reduced glutathione when compared to controls. However, after 30 days of oral administration of corilagin (10 and 20 mg/kg bw/day) to these diabetic rats evoked significant alterations in the above mentioned parameters. The effect of corilagin was compared with the standard drug, glibenclamide (0.1 mg/kg body weight/day). Thus, the present study suggests that the corilagin acts as a natural, effective therapeutic agent to regulate diabetes, by exhibiting antidiabetic, antihyperlipidemic and antioxidant properties in STZ induced diabetic rats. •The world's largest endocrine disease involving metabolic disorders is diabetes mellitus.•Drug prescription remains to be the major successful approach to improve diabetic condition.•Corilagin is a member of polyphenolic tannins.•Corilagin has a potential to regulate diabetes.•It exhibits antidiabetic, antihyperlipidemic and antioxidant properties in STZ induced diabetic rats.